Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:
”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.
This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.
Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.
Patients living with HHT can’t wait for effective therapies to improve their lives.”
Quoting Vaderis Therapeutics AG‘s post:
”Moving Forward Together for the HHT Community
We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).
This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.
While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.
As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.
Read the full press release.”
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 05:32Why TXA and rFVIIa Are Not Equivalent in Trauma Bleeding Control – RPTH Journal
-
Apr 23, 2026, 04:08Suraj Mali: Pune Team Initiative for World Hemophilia Day 2026 Advances Early Diagnosis in Hemophilia
-
Apr 23, 2026, 03:58Adam Ho: What Does It Actually Mean to ”Prevent” a Stroke?
-
Apr 23, 2026, 03:49Jakob Krebs Christensen: Mobile Stroke Units Bring Imaging and Treatment Directly to the Patient
-
Apr 23, 2026, 03:30Kimberly Waddell: Mismatch in Post-Stroke Discharge Decisions Impacts Long-Term Recovery
-
Apr 23, 2026, 03:18Pablo Corral: Key Take‑Home Messages on Familial Hypercholesterolemia
-
Apr 23, 2026, 03:17Wolfgang Miesbach: The Haemophilia A Gene Therapy Story Is Moving from West to China
-
Apr 23, 2026, 02:17Francisco Chacón-Lozsán: Pulmonary Artery Catheter in Cardiogenic Shock From Obsolete Device to Modern Decision Tool
-
Apr 23, 2026, 01:33Maha Othman: Our Research Group Had a Highly Successful Showing at the ISLH 2026 Congress